<DOC>
	<DOCNO>NCT02954926</DOCNO>
	<brief_summary>Majority healthcare authority believe due methodological weakness small number patient conduct therapeutic trial , evidence insufficient support efficacy intravenous immunoglobulin ( IVIG ) prevention preterm neonatal sepsis . The objective research determine effect intravenous immunoglobulin prevention preterm neonatal sepsis .</brief_summary>
	<brief_title>Intravenous Immunoglobulin Prevention Preterm Neonatal Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Born alive 37 week pregnancy ( preterm neonate ) Under 2500 g birth lethal anomaly congenital heart disease TORCH infection severe asphyxia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>